CancerNCT07093567
Opiophobia in Adults With Advanced Cancer
An observational study of Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To explore the barriers and fears related to use of opioids among a population of adult outpatients with advanced cancer who continue to experience pain after receiving a prescription for opioid analgesia and hypothesized associations among opiophobia, anxiety, depression, pain intensity, pain interference, and opioid… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2025to 1 Jan 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Adult patients with advanced cancer (defined as cancer that is unlikely to be cured and is locally advanced or distantly metastasized
- Pain is the documented reason for the Supportive Care consultation
- Have a prescription for an opioid analgesic
- Able to read, speak, and consent in English.
Who cannot join
- Age less than 18 years
- Do not have a prescription for an opioid analgesic
- Individuals for whom there is documentation of inability to provide consent in the medical record
- Women who are pregnant
- Patients with a substance use disorder (including alcohol use disorder and excluding tobacco use disorder) documented in the electronic health record under History of Present Illness or in the Medical History.
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030
About this study
To explore the barriers and fears related to use of opioids among a population of adult outpatients with advanced cancer who continue to experience pain after receiving a prescription for opioid analgesia and hypothesized associations among opiophobia, anxiety, depression, pain intensity, pain interference, and opioid medication adherence.
Read the detailed description
Primary Objective:
To explore the barriers and fears related to use of opioids among a population of adult outpatients with advanced cancer who continue to experience pain after receiving a prescription for opioid analgesia.
Secondary Objective:
To examine associations among opiophobia, anxiety, depression, pain intensity, pain interference, and opioid medication adherence among adults with advanced cancer who report undermanaged pain during the first week after receiving a prescription for an opioid analgesic.
- Conditions
- Cancer
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Barriers Questionnaire (BQ-13)
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2025
- Study start1 Aug 2025
- Primary completion1 Jan 2029 (estimated)
- Study completion1 Jan 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eileen Hacker, PHD, RN, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07093567
- Sponsor's protocol ID
- 2025-0177
- Other IDs
- NCI-2025-05283
- Status last verified
- Sep 2026
- First submitted
- 23 Jul 2025
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Opiophobia in Adults With Advanced Cancer
- ClinicalTrials.gov ID
- NCT07093567
- Acronym / sponsor ID
- 2025-0177
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 1 Jan 2029 (estimated)
- Study completion
- 1 Jan 2031 (estimated)
- First posted
- 30 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore the barriers and fears related to use of opioids among a population of adult outpatients with advanced cancer who continue to experience pain after receiving a prescription for opioid analgesia and hypothesized associations among opiophobia, anxiety, depression, pain intensity, pain interference, and opioid medication adherence.
Detailed description
Primary Objective:
To explore the barriers and fears related to use of opioids among a population of adult outpatients with advanced cancer who continue to experience pain after receiving a prescription for opioid analgesia.
Secondary Objective:
To examine associations among opiophobia, anxiety, depression, pain intensity, pain interference, and opioid medication adherence among adults with advanced cancer who report undermanaged pain during the first week after receiving a prescription for an opioid analgesic.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (4 listed)
- Adult patients with advanced cancer (defined as cancer that is unlikely to be cured and is locally advanced or distantly metastasized
- Pain is the documented reason for the Supportive Care consultation
- Have a prescription for an opioid analgesic
- Able to read, speak, and consent in English.
Key exclusion criteria (5 listed)
- Age less than 18 years
- Do not have a prescription for an opioid analgesic
- Individuals for whom there is documentation of inability to provide consent in the medical record
- Women who are pregnant
- Patients with a substance use disorder (including alcohol use disorder and excluding tobacco use disorder) documented in the electronic health record under History of Present Illness or in the Medical History.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Barriers Questionnaire (BQ-13)
Time frame: Through study completion; an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eileen Hacker, PHD, RN principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Barriers Questionnaire (BQ-13) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.